Bloom Pod

Dr. Vinh Dao & Dr. Shray Amin

Bridging Learning in Oncology and Medicine The BLOOM podcast is an oncology-based podcast focused on promoting new advances in oncology and how these advances relate to other sub-specialties in medicine.

Episodes

  1. 2025-06-18

    Anticoagulation for Cancer Patients

    Works Cited: 1. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599–607. 2. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017–23. 3. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342–52. 4. Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615–24. 5. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003 Jul 10;349(2):146–53. 6. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. JCO. 2023 Jun 1;41(16):3063–71.

    8 min

  2. 2025-06-04

    Pain Management for Cancer Patients

    Works Cited: 1. National Cancer Institute. Cancer Pain (PDQ®)–Health Professional Version. PDQ® Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2025 Apr 24 [cited 2025 Jul 16]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq 2. University of Virginia School of Nursing. Pain is personal; relief from cancer pain should be, too [Internet]. Charlottesville (VA): University of Virginia School of Nursing; 2021 Feb 11 [cited 2025 Jul 16]. Available from: https://nursing.virginia.edu/news/lebaron-cancer-pain-nih 3. OncLive Staff. Non-pharmacologic therapies for pain management in patients with cancer: Opportunities and challenges [Internet]. Cranbury (NJ): OncLive; [date unknown] [cited 2025 Jul 16]. Available from: https://www.onclive.com/view/non-pharmacologic-therapies-for-pain-management-in-patients-with-cancer-opportunities-and-challenges 4. Mestdagh F, Steyaert A, Lavand’homme P. Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques. Curr Oncol. 2023 Jul 18;30(7):6838–58. 5. Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book. 2015;e593-599. 6. Mercadante S. Cancer Pain Treatment Strategies in Patients with Cancer. Drugs. 2022 Sep;82(13):1357–66. 7. Haroun R, Wood JN, Sikandar S. Mechanisms of cancer pain. Front Pain Res (Lausanne). 2022;3:1030899. 8. Rosenscheg M, Pedron J, Pedroso L. Treatment of Cancer Pain: A Systematic Review. Am J Clin Oncol. 2023 Oct 1;46(10):450–8.

    5 min

  3. 2025-04-09

    TACO vs. TRALI

    Transfusions are often a critical component for patients receiving myelosuppressive chemotherapy. However, it is important to know some key transfusion complications and how to differentiate between TACO and TRALI. Works Cited: 1. Wiersum-Osselton, Johanna C et al. “Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study.” The Lancet. Haematology vol. 6,7 (2019): e350-e358. doi:10.1016/S2352-3026(19)30080-8 2. Vlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, Bolton-Maggs P, Peters AL, Silliman CC, Kor DJ, Kleinman S. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019 Jul;59(7):2465-2476. doi: 10.1111/trf.15311. Epub 2019 Apr 16. PMID: 30993745; PMCID: PMC6850655. 3. van den Akker, Tayler A et al. “Transfusion-Associated Circulatory Overload and Transfusion-Related Acute Lung Injury.” American journal of clinical pathology vol. 156,4 (2021): 529-539. doi:10.1093/ajcp/aqaa279 4. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematology. 2018;2018(1):585-594. doi:10.1182/asheducation-2018.1.585 5. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med. 2006 May;34(5 Suppl):S109-13. doi: 10.1097/01.CCM.0000214311.56231.23. PMID: 16617253. 6. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood. 2019;133(17):1840-1853. doi:10.1182/blood-2018-10-860809

    13 min

  4. 2025-03-26

    Hyperviscosity Syndrome

    Works Cited: 1. Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018 Sep 27;132(13):1379–85. 2. Weaver A, Rubinstein S, Cornell RF. Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Front Oncol. 2020;10:815. 3. Daniel R, Chan RY. Hyperviscosity syndrome in splenic marginal zone lymphoma. Blood. 2018 Oct 11;132(15):1627. 4. Bey T, Qdaisat A. Hyperviscosity Syndrome: An Oncologic Emergency. Emerg Med Clin North Am. 2025 Aug;43(3):445–52. 5. Musick JO, Fibben KS, Lam WA. Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices. Curr Opin Hematol. 2022 Nov 1;29(6):290–6.

    7 min

  5. 2025-03-12

    Neutropenic Fever

    Works Cited: 1. Gould Rothberg BE, Quest TE, Yeung SJ, et al. Oncologic emergencies and urgencies: A comprehensive review. CA Cancer J Clin. 2022;72(6):570-593. doi:10.3322/caac.21727 2. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment [published correction appears in CA Cancer J Clin. 2011 Nov-Dec;61(6):420. Dosage error in article text]. CA Cancer J Clin. 2011;61(5):287-314. doi:10.3322/caac.20124 3. Higdon ML, Atkinson CJ, Lawrence KV. Oncologic Emergencies: Recognition and Initial Management. Am Fam Physician. 2018;97(11):741-748. 4. Halfdanarson TR, Hogan WJ, Madsen BE. Emergencies in Hematology and Oncology. Mayo Clin Proc. 2017;92(4):609-641. doi:10.1016/j.mayocp.2017.02.008 5. Lucas AJ, Olin JL, Coleman MD. Management and Preventive Measures for Febrile Neutropenia. P T. 2018 Apr;43(4):228-232. PMID: 29622943; PMCID: PMC5871243. 6. Choi, Jennifer et al. “Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 28,12 (2020): 6119-6128. doi:10.1007/s00520-020-05706-4 7. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. JCO. 2015 Oct 1;33(28):3199–212. 8. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21;368(12):1131-9. doi: 10.1056/NEJMct1210890. Erratum in: N Engl J Med. 2013 Jul 18;369(3):293. Dosage error in article text. PMID: 23514290; PMCID:

    12 min

  6. 2025-02-27

    Radiation-Induced Cardiovascular Diseases

    Works Cited: 1. Hirshfeld JW, Ferrari VA, Bengel FM, Bergersen L, Chambers CE, Einstein AJ, et al. 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging—Best Practices for Safety and Effectiveness, Part 1: Radiation Physics and Radiation Biology. Journal of the American College of Cardiology. 2018 Jun;71(24):2811–28. 2. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology. 2017 Nov;70(20):2552–65. 3. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018 Oct;104(20):1647–53. 4. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann M, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. JCO. 2016 Jan 20;34(3):235–43. 5. Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, et al. Radiation-Induced Endothelial Vascular Injury. JACC: Basic to Translational Science. 2018 Aug;3(4):563–72. 6. Belzile‐Dugas E, Eisenberg MJ. Radiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology. JAHA [Internet]. 2021 Sep 21 [cited 2025 Jul 10];10(18). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.121.021686 7. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol ADG, et al. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. JNCI: Journal of the National Cancer Institute [Internet]. 2015 Apr [cited 2025 Jul 10];107(4). Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv008 8. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. N Engl J Med. 2013 Mar 14;368(11):987–98. 9. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin’s Disease. JCO. 2007 Jan 1;25(1):43–9.

    18 min

  7. 2025-02-05

    Early Palliative Care

    Works Cited: 1. Petrillo, Laura A et al. “Why and How to Integrate Early Palliative Care Into Cutting-Edge Personalized Cancer Care.” American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting vol. 44,3 (2024): e100038. doi:10.1200/EDBK_100038 2. Haun, Markus W et al. “Early palliative care for adults with advanced cancer.” The Cochrane database of systematic reviews vol. 6,6 CD011129. 12 Jun. 2017, doi:10.1002/14651858.CD011129.pub2 3. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A, Lo C. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014 May 17;383(9930):1721-30. doi: 10.1016/S0140-6736(13)62416-2. Epub 2014 Feb 19. PMID: 24559581. 4. Temel JS, Jackson VA, El-Jawahri A, Rinaldi SP, Petrillo LA, Kumar P, McGrath KA, LeBlanc TW, Kamal AH, Jones CA, Rabideau DJ, Horick N, Pintro K, Gallagher Medeiros ER, Post KE, Greer JA. Stepped Palliative Care for Patients With Advanced Lung Cancer: A Randomized Clinical Trial. JAMA. 2024 Aug 13;332(6):471-481. doi: 10.1001/jama.2024.10398. PMID: 38824442; PMCID: PMC11145511. 5. Vanbutsele G, Pardon K, Van Belle S, Surmont V, De Laat M, Colman R, Eecloo K, Cocquyt V, Geboes K, Deliens L. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018 Mar;19(3):394-404. doi: 10.1016/S1470-2045(18)30060-3. Epub 2018 Feb 3. PMID: 29402701.

    6 min

  8. 2025-01-15

    Artificial Intelligence in Oncology

    Works Cited 1. National Cancer Institute. Artificial Intelligence in Cancer Research [Internet]. Bethesda (MD): National Cancer Institute; [cited 2025 Jul 10]. Available from: https://www.cancer.gov/research/infrastructure/artificial-intelligence 2. Steyaert S, Qiu YL, Zheng Y, Mukherjee P, Vogel H, Gevaert O. Multimodal deep learning to predict prognosis in adult and pediatric brain tumors. Commun Med (Lond). 2023 Mar 29;3(1):44. doi: 10.1038/s43856-023-00276-y. PMID: 36991216; PMCID: PMC10060397. 3. Amgad M, Hodge JM, Elsebaie MAT, Bodelon C, Puvanesarajah S, Gutman DA, Siziopikou KP, Goldstein JA, Gaudet MM, Teras LR, Cooper LAD. A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer. Nat Med. 2024 Jan;30(1):85-97. doi: 10.1038/s41591-023-02643-7. Epub 2023 Nov 27. PMID: 38012314. 4. Hollon T, Jiang C, Chowdury A, Nasir-Moin M, Kondepudi A, Aabedi A, Adapa A, Al-Holou W, Heth J, Sagher O, Lowenstein P, Castro M, Wadiura LI, Widhalm G, Neuschmelting V, Reinecke D, von Spreckelsen N, Berger MS, Hervey-Jumper SL, Golfinos JG, Snuderl M, Camelo-Piragua S, Freudiger C, Lee H, Orringer DA. Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging. Nat Med. 2023 Apr;29(4):828-832. doi: 10.1038/s41591-023-02252-4. Epub 2023 Mar 23. PMID: 36959422; PMCID: PMC10445531. 5. Alawad M, Gao S, Qiu JX, Yoon HJ, Blair Christian J, Penberthy L, Mumphrey B, Wu XC, Coyle L, Tourassi G. Automatic extraction of cancer registry reportable information from free-text pathology reports using multitask convolutional neural networks. J Am Med Inform Assoc. 2020 Jan 1;27(1):89-98. doi: 10.1093/jamia/ocz153. PMID: 31710668; PMCID: PMC7489089. 6. Placido D, Yuan B, Hjaltelin JX, Zheng C, Haue AD, Chmura PJ, Yuan C, Kim J, Umeton R, Antell G, Chowdhury A, Franz A, Brais L, Andrews E, Marks DS, Regev A, Ayandeh S, Brophy MT, Do NV, Kraft P, Wolpin BM, Rosenthal MH, Fillmore NR, Brunak S, Sander C. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med. 2023 May;29(5):1113-1122. doi: 10.1038/s41591-023-02332-5. Epub 2023 May 8. PMID: 37156936; PMCID: PMC10202814.

    7 min

  9. 2024-12-29

    Chemotherapy-induced Cardiotoxicity

    Works Cited 1. Gao Y, Wang R, Jiang J, Hu Y, Li H, Wang Y. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. Heart Fail Rev. 2023 Nov;28(6):1405-1415. doi: 10.1007/s10741-023-10328-z. Epub 2023 Jul 7. PMID: 37414918; PMCID: PMC10575808. 2. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868. doi: 10.1016/j.jacc.2019.03.495. PMID: 31171092; PMCID: PMC6557296. 3. Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018 Aug 31;1(1):13-17. doi: 10.1093/abt/tby003. PMID: 30215054; PMCID: PMC6131716. 4. Moslehi JJ, Witteles RM. Global Longitudinal Strain in Cardio-Oncology. J Am Coll Cardiol. 2021 Feb 2;77(4):402-404. doi: 10.1016/j.jacc.2020.12.014. PMID: 33509396; PMCID: PMC8397591. 5. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023 Mar;16(3):269-278. doi: 10.1016/j.jcmg.2022.10.010. Epub 2022 Nov 16. PMID: 36435732. 6. Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, Tsutsui H. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 2019 Oct;108(10):1128-1139. doi: 10.1007/s00392-019-01448-4. Epub 2019 Mar 11. PMID: 30859381. 7. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019 Oct 1;4(10):1007-1018. doi: 10.1001/jamacardio.2019.2952. PMID: 31433450; PMCID: PMC6705141. 8. Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022 Mar 15;4(1):19-37. doi: 10.1016/j.jaccao.2022.01.101. PMID: 35492815; PMCID: PMC9040117.

    9 min

  10. 2024-11-03

    CRS and ICANS

    Cytokine Release Storm and Immune effector Cell-Associated Neurotoxicity Syndrome Works Cited: 1. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy Gazeau, Nicolas et al.Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 29, Issue 7, 430 - 437 2. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi:10.1056/NEJMra2026131. PMID: 33264547; PMCID: PMC7727315. 3. Garcia Borrega J, Gödel P, Rüger MA, Onur ÖA, Shimabukuro-Vornhagen A, Kochanek M, Böll B. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere. 2019 Mar 29;3(2):e191. doi:10.1097/HS9.0000000000000191. PMID: 31723828; PMCID: PMC6746039. 4. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014 Oct 28;5:235. doi:10.3389/fphar.2014.00235. PMID: 25389405; PMCID: PMC4211380. 5. Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023 May 18;141(20):2430-2442. doi:10.1182/blood.2022017414. PMID: 36989488; PMCID: PMC10329191. 6. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. PMID: 30592986. 7. Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine Release Syndrome: Current Perspectives Immunotargets Ther. 2019 Oct 29;8:43-52. doi:10.2147/ITT.S202015. PMID: 31754614; PMCID: PMC6825470.Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. 2023 May 25;14:1190379. doi:10.3389/fimmu.2023.1190379. PMID: 37304291; PMCID: PMC10248525. 8. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018 Jun 15;6(1):56. doi:10.1186/s40425-018-0343-9. PMID: 29907163; PMCID: PMC6003181.

    11 min
  • 10 Episodes

About

Bridging Learning in Oncology and Medicine The BLOOM podcast is an oncology-based podcast focused on promoting new advances in oncology and how these advances relate to other sub-specialties in medicine.

Information

  • Creator
    Dr. Vinh Dao & Dr. Shray Amin
  • Years Active
    2024 - 2025
  • Episodes
    10